Despite the PD-L1 expression and tumor mutational burden (TMB) have been broadly studied in many other tumors as a ICIs predictive biomarker, their applicability in ccRCC have not been demonstrated, mainly due to their unclear cutoff for positivity, intratumoral heterogeneity and inconsistency between primary tumor and metastasis [172]. The gene discussed is CD274; the disease is neoplasm.